Previous Article | Next Article 
Infection and Immunity, February 2005, p. 828-833, Vol. 73, No. 2
0019-9567/05/$08.00+0 doi:10.1128/IAI.73.2.828-833.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
CpG Oligodeoxynucleotides Adsorbed onto Polylactide-Co-Glycolide Microparticles Improve the Immunogenicity and Protective Activity of the Licensed Anthrax Vaccine
Hang Xie,1
Ihsan Gursel,1
Bruce E. Ivins,2
Manmohan Singh,3
Derek T. O'Hagan,3
Jeffrey B. Ulmer,3 and
Dennis M. Klinman1*
Section of Retroviral Immunology, Center for Biologics Evaluation Research, Food and Drug Administration, Bethesda,1
Bacteriology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland,2
Chiron Vaccines, Emeryville, California3
Received 9 August 2004/
Returned for modification 14 September 2004/
Accepted 3 October 2004
To reduce the biothreat posed by anthrax, efforts are under way to improve the protection afforded by vaccination. This work examines the ability of immunostimulatory CpG oligodeoxynucleotides (ODN) adsorbed onto cationic polylactide-co-glycolide (PLG) microparticles (CpG ODN-PLG) to accelerate and boost the protective immunity elicited by Anthrax Vaccine Adsorbed (AVA, the licensed human anthrax vaccine). The results indicate that coadministering CpG ODN-PLG with AVA induces a stronger and faster immunoglobulin G response against the protective antigen of anthrax than AVA alone. Immunized mice were protected from lethal anthrax challenge within 1 week of vaccination with CpG ODN-PLG plus AVA, with the level of protection correlating with serum immunoglobulin G anti-protective antigen titers.
* Corresponding author. Mailing address: Center for Biologics Evaluation Research, Food and Drug Administration, Bldg. 29A, Rm. 3D10, Bethesda, MD 20892. Phone: (301) 827-1707. Fax: (301) 496-1810. E-mail:
Klinman{at}cber.fda.gov.
Editor: J. D. Clements
Infection and Immunity, February 2005, p. 828-833, Vol. 73, No. 2
0019-9567/05/$08.00+0 doi:10.1128/IAI.73.2.828-833.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Oscherwitz, J., Yu, F., Cease, K. B.
(2009). A Heterologous Helper T-Cell Epitope Enhances the Immunogenicity of a Multiple-Antigenic-Peptide Vaccine Targeting the Cryptic Loop-Neutralizing Determinant of Bacillus anthracis Protective Antigen. Infect. Immun.
77: 5509-5518
[Abstract]
[Full Text]
-
Thomas, J. M., Moen, S. T., Gnade, B. T., Vargas-Inchaustegui, D. A., Foltz, S. M., Suarez, G., Heidner, H. W., Konig, R., Chopra, A. K., Peterson, J. W.
(2009). Recombinant Sindbis Virus Vectors Designed To Express Protective Antigen of Bacillus anthracis Protect Animals from Anthrax and Display Synergy with Ciprofloxacin. CVI
16: 1696-1699
[Abstract]
[Full Text]
-
Tross, D., Klinman, D. M.
(2008). Effect of CpG Oligonucleotides on Vaccine-Induced B Cell Memory. J. Immunol.
181: 5785-5790
[Abstract]
[Full Text]
-
Klinman, D., Shirota, H., Tross, D., Sato, T., Klaschik, S.
(2008). Synthetic oligonucleotides as modulators of inflammation. J. Leukoc. Biol.
84: 958-964
[Abstract]
[Full Text]
-
Grabenstein, J. D., Pittman, P. R., Greenwood, J. T., Engler, R. J.M.
(2006). Immunization to Protect the US Armed Forces: Heritage, Current Practice, and Prospects. Epidemiol Rev
28: 3-26
[Abstract]
[Full Text]